In a significant portfolio change, Point72, the investment firm led by Steve Cohen, liquidated its entire stake in Pfizer (PFE). The firm sold all 4.37 million of its shares, a position previously valued at approximately $122.57 million.
This activity was revealed in a quarterly 13F filing with the SEC, which discloses trades made during the second quarter ending June 30, 2026. The exit occurred during a period where Pfizer later reported a 3% year-over-year revenue increase for the quarter and raised its full-year revenue guidance. The filing reflects past trading activity and does not indicate the firm's current-day holdings.